The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.

ABSTRACT:

Background & aims

It is unknown whether the addition of locoregional therapies (LRTx) to sorafenib improves prognosis over sorafenib alone in patients with advanced hepatocellular carcinoma (HCC). The aim of this study was to assess the effect of LRTx in this population.

Methods

A retrospective analysis was performed of patients with advanced HCC as defined by extrahepatic metastasis, lymphadenopathy >2 cm, or gross vascular invasion. Sorafenib therapy was required for inclusion. Survival of patients who received LRTx after progression to advanced stage was compared to those who did not receive LRTx.

Results

Using an intention to treat analysis of 312 eligible patients, a propensity weighted proportional hazards model demonstrated LRTx as a predictor of survival (HR =

SUBMITTER: Sarpel U 

PROVIDER: S-EPMC4857060 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature